• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
ConclusionsThis large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.
Source: Drug Safety - August 1, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy of trazodone for treating paroxysmal sympathetic hyperactivity presenting after thalamic hemorrhage: A case report.
Authors: Morinaga Y, Nii K, Sakamoto K, Inoue R, Mitsutake T, Hanada H Abstract Paroxysmal sympathetic hyperactivity (PSH) is a clinical condition characterized by abnormal paroxysmal surges in sympathetic nervous system activity. PSH is known to occur after severe head injury and hypoxic encephalopathy. Cases of PSH that develop after stroke have been reported worldwide; however, PSH is not commonly reported in the field of stroke research in Japan. Some studies have suggested that gabapentin may improve the symptoms of PSH. To our knowledge, this is the first case report demonstrating the efficacy of trazodone fo...
Source: Drug Discoveries and Therapeutics - July 23, 2019 Category: Drugs & Pharmacology Tags: Drug Discov Ther Source Type: research

Cardiovascular Safety of the β3 -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial.
Abstract There have been concerns that treatment of overactive bladder with β3 -adrenoceptor agonists may potentially have detrimental cardiovascular (CV) side effects. We evaluated the CV safety of mirabegron, a β3 -adrenoceptor agonist, alone and in combination therapy with the antimuscarinic agent solifenacin. The SYNERGY trial was a multinational, multicenter, randomized, double-blind, parallel-group, placebo and active-controlled phase 3 trial. Patients were randomized to receive solifenacin 5 mg + mirabegron 50 mg (combination 5 + 50 mg), solifenacin 5 mg + mirabegron 25 mg (combination 5 + 2...
Source: The Journal of Clinical Pharmacology - April 12, 2018 Category: Drugs & Pharmacology Authors: White WB, Chapple C, Gratzke C, Herschorn S, Robinson D, Frankel J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Weber MA Tags: J Clin Pharmacol Source Type: research

Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study
ConclusionsWe did not identify differences in the risk of cardiovascular events or mortality among users of individual antimuscarinic OAB drugs.
Source: European Journal of Clinical Pharmacology - November 13, 2017 Category: Drugs & Pharmacology Source Type: research